Your browser doesn't support javascript.
loading
Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy.
Landon-Cardinal, Océane; Allenbach, Yves; Soulages, Antoine; Rigolet, Aude; Hervier, Baptiste; Champtiaux, Nicolas; Monzani, Quentin; Solé, Guilhem; Benveniste, Olivier.
Affiliation
  • Landon-Cardinal O; From the Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, AP-HP, East Paris Neuromuscular Diseases Reference Center, Inserm U974, Sorbonne Université, Paris, France; Center of Reference for Ne
  • Allenbach Y; Dr. Landon-Cardinal is the recipient of Clinical Fellowship awards from the Université de Montréal Rheumatology Program, Abbvie Educational Grant and the Association des médecins rhumatologues du Québec, Visithan-Khy Educational Grant. o.landoncardinal@gmail.com.
  • Soulages A; O. Landon-Cardinal, MD, Myositis post-doctoral Fellowship, Department of Internal Medicine and Clinical Immunology, AP-HP, Hôpital Pitié-Salpêtrière; Y. Allenbach, MD, PhD, Assistant Professor of Medicine, Department of Internal Medicine and Clinical Immunology, AP-HP, Hôpital Pitié-Salpêtrière; A.
  • Rigolet A; From the Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, AP-HP, East Paris Neuromuscular Diseases Reference Center, Inserm U974, Sorbonne Université, Paris, France; Center of Reference for Ne
  • Hervier B; Dr. Landon-Cardinal is the recipient of Clinical Fellowship awards from the Université de Montréal Rheumatology Program, Abbvie Educational Grant and the Association des médecins rhumatologues du Québec, Visithan-Khy Educational Grant.
  • Champtiaux N; O. Landon-Cardinal, MD, Myositis post-doctoral Fellowship, Department of Internal Medicine and Clinical Immunology, AP-HP, Hôpital Pitié-Salpêtrière; Y. Allenbach, MD, PhD, Assistant Professor of Medicine, Department of Internal Medicine and Clinical Immunology, AP-HP, Hôpital Pitié-Salpêtrière; A.
  • Monzani Q; From the Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, AP-HP, East Paris Neuromuscular Diseases Reference Center, Inserm U974, Sorbonne Université, Paris, France; Center of Reference for Ne
  • Solé G; Dr. Landon-Cardinal is the recipient of Clinical Fellowship awards from the Université de Montréal Rheumatology Program, Abbvie Educational Grant and the Association des médecins rhumatologues du Québec, Visithan-Khy Educational Grant.
  • Benveniste O; O. Landon-Cardinal, MD, Myositis post-doctoral Fellowship, Department of Internal Medicine and Clinical Immunology, AP-HP, Hôpital Pitié-Salpêtrière; Y. Allenbach, MD, PhD, Assistant Professor of Medicine, Department of Internal Medicine and Clinical Immunology, AP-HP, Hôpital Pitié-Salpêtrière; A.
J Rheumatol ; 46(6): 623-627, 2019 06.
Article in En | MEDLINE | ID: mdl-30554155
ABSTRACT

OBJECTIVE:

A pathogenic role of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibodies has been proposed. Our objective was to assess efficacy of rituximab (RTX) in anti-HMGCR immune-mediated necrotizing myopathy.

METHODS:

All patients who had been treated with RTX were retrospectively reviewed to assess features and outcome.

RESULTS:

Three of 9 patients demonstrated stable or improved muscle strength ± decline in creatine kinase levels, or T2/short-tau inversion recovery hypersignal decrease on magnetic resonance imaging following RTX treatment. RTX permitted intravenous immunoglobulin discontinuation and corticosteroid reduction to low dose in 2 patients.

CONCLUSION:

One-third of patients with refractory anti-HMGCR had improved strength or other evidence of improved disease activity following RTX treatment.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoimmune Diseases / Rituximab / Hydroxymethylglutaryl CoA Reductases / Immunologic Factors / Myositis Type of study: Observational_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Rheumatol Year: 2019 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoimmune Diseases / Rituximab / Hydroxymethylglutaryl CoA Reductases / Immunologic Factors / Myositis Type of study: Observational_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Rheumatol Year: 2019 Document type: Article